Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude du JNJ-1761981 chez des participants atteints de tumeurs solides

2 novembre 2026 mis à jour par: Johnson & Johnson Enterprise Innovation Inc.

Étude de Phase 1 de l'administration intratumorale de JNJ-1761981 ER, une chimiothérapie à libération prolongée, chez des participants atteints de tumeurs solides

The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.

Aperçu de l'étude

Statut

Recrutement

Les conditions

Type d'étude

Interventionnel

Inscription (Estimé)

66

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Florida
      • Jacksonville, Florida, États-Unis, 32224
        • Recrutement
        • Mayo Clinic in Florida
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Recrutement
        • Mayo Clinic Rochester
    • New York
      • The Bronx, New York, États-Unis, 10467
        • Recrutement
        • Montefiore Medical Center
    • Texas
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • MD Anderson Cancer Center

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion criteria:

  • Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system [CNS]) who have previously received available standard therapy and progressed, or cannot tolerate standard therapy, or for whom there is no standard of care per regional guidelines
  • Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology, for which any platinum-based systemic regimen is considered a standard of care (per national comprehensive cancer network [NCCN] guidelines) and whose disease has progressed after standard therapy
  • Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1
  • Part 2 Cohort A participants planned to receive optional cetrelimab (participants not meeting this criterion may still be enrolled in the study but cannot receive cetrelimab): Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
  • A participant of childbearing potential must practice at least 2 highly effective methods of contraception throughout the study and through 14 months (for women) and 11 months (for men) after the last dose of JNJ-1761981 or 5 months after the last dose of cetrelimab or other anti-PD(L)1 treatment, whichever is later

Exclusion criteria:

  • Active symptomatic disease involvement of the central nervous system
  • Prior or concurrent second malignancy (other than the disease under study) that due to natural history or treatment is likely to interfere with any study endpoints of safety or the antitumor activity of the study treatment(s)
  • Active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures
  • Known allergies, hypersensitivity, or intolerance to JNJ-1761981 or its excipients
  • Lesions invading or adjacent to major blood vessels or other critical structures (for example, airways) not suitable for injection

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1: Dose Escalation

Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total JNJ-1761981 dose.

JNJ-1761981 will be administered intratumorally.

Expérimental: Part 2: Dose Expansion

Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses. Participants who receive more than 1 dose of JNJ-1761981 may receive optional systemic therapy with cetrelimab at the discretion of the treating physician.

JNJ-1761981 will be administered intratumorally.

Cetrelimab will be administered intravenously.

Autres noms:
  • JNJ-63723283

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part 1: Number of Participants with Adverse Events (AE) by Severity
Délai: Up to approximately 2 years 10 months

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.

Up to approximately 2 years 10 months
Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
Délai: Up to 28 days

High grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation will be regarded as DLT.

Up to 28 days
Part 1: Number of Participants with AEs by Severity Related to Delivery Device and/or Procedure
Délai: Up to approximately 2 years 10 months

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported.

Up to approximately 2 years 10 months
Part 1: Number of Participants who Received Planned Total Dose per Level
Délai: Up to approximately 28 days

Number of participants who received planned total dose per level will be reported.

Up to approximately 28 days
Part 2: Administered Tumor Response Rate
Délai: Up to approximately 2 years 10 months

Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve complete response (CR) or partial response (PR).

Up to approximately 2 years 10 months

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Parts 1 and 2: Plasma Concentration of Free and Total Platinum
Délai: Up to approximately 2 years 10 months

Plasma concentration of free and total platinum will be assessed.

Up to approximately 2 years 10 months
Part 1: Administered Tumor Response Rate
Délai: Up to approximately 2 years 10 months

Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve CR or PR.

Up to approximately 2 years 10 months
Parts 1 and 2: Administered Tumor Duration of Response
Délai: Up to approximately 2 years 10 months

Administered tumor duration of response will be calculated among JNJ-1761981 administered lesions that responded from the date of initial documentation of lesion response to the date of first documented evidence of progression or start of subsequent anticancer treatment or death due to any cause, whichever occurs first.

Up to approximately 2 years 10 months
Parts 1 and 2: Objective Response Rate (ORR)
Délai: Up to approximately 2 years 10 months

ORR is defined as the percentage of participants who have best response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Up to approximately 2 years 10 months
Parts 1 and 2: Disease Control Rate (DCR)
Délai: Up to approximately 2 years 10 months

DCR is defined as the percentage of participants who have achieved CR, PR, and stable disease for at least 4 weeks after study treatment was administered.

Up to approximately 2 years 10 months
Parts 1 and 2: Duration of Response (DOR)
Délai: Up to approximately 2 years 10 months

DOR will be calculated among responders from the date of initial documentation of a response (first CR/PR) to the date of first documented evidence of progression according to RECIST v.1.1, or death due to any cause, whichever occurs first.

Up to approximately 2 years 10 months
Part 2: Number of Participants with Adverse Events (AE) by Severity
Délai: Up to approximately 2 years 10 months

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the NCI-CTCAE v 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE.

Up to approximately 2 years 10 months
Part 2: Number of Participants with AE by Severity Related to Delivery Device and/or Procedure
Délai: Up to approximately 2 years 10 months

An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported.

Up to approximately 2 years 10 months
Part 2: Number of Participants who Received Planned Intratumoral Volumetric Dose
Délai: Up to approximately 2 years 10 months

Number of participants who received the planned intratumoral volumetric dose will be reported.

Up to approximately 2 years 10 months

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Johnson & Johnson Enterprise Innovation, Inc Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

18 mai 2026

Achèvement primaire (Estimé)

12 janvier 2028

Achèvement de l'étude (Estimé)

31 janvier 2029

Dates d'inscription aux études

Première soumission

6 avril 2026

Première soumission répondant aux critères de contrôle qualité

6 avril 2026

Première publication (Réel)

13 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

3 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

2 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Termes MeSH pertinents supplémentaires

Autres numéros d'identification d'étude

  • 1761981STM1001
  • 1761981STM1001 (Autre identifiant: Janssen Research & Development, LLC)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner